ASIA-PACIFIC OPIOID DRUGS MARKET 2019-2028

Lifesciences | Pharmaceuticals

ASIA-PACIFIC OPIOID DRUGS MARKET 2019-2028

Market By Product, Application, And Geography | Forecast 2019-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The Asia-Pacific opioid drugs market is expected to make progress at a CAGR of 3.05% in terms of revenue throughout the estimated period 2019-2028.


Report scope can be customized per your requirements. Request For Customization

The countries studied in this market include:

           China

           Japan

           South Korea

           ASEAN countries

           Australia & New Zealand

           India

           Rest of APAC

China, being a highly populous country, has a huge number of cancer patients. It is estimated that, each year, around 1.8 million patients are found to be affected by cancer, and 1.4 million patients die from this deadly condition. Considering the urban population, cancer is the primary cause of death, among all commonly occurring diseases; whereas, considering the population in the rural areas, it is the second-leading cause of death. Whether it is cancer-associated or non-cancer-associated pain, pain management is a critical issue in the care of patients suffering from both. Opioid drugs have proven extremely beneficial in this scenario, owing to their role in pain management. This is helping the growth of the Chinese opioid drugs market over the forecast period.

As per a report, the consumption of opioid analgesics in Japan is 15.5%, considering the calculated requirement. This is remarkably low, when compared with other nations, such as the US, France, and the UK. However, in recent years, owing to the expansion of opioid indications to include non-cancer chronic pain, the annual consumption of opioid drugs in the country is expected to increase. Owing to this increase in consumption, it is predicted that the inappropriate use of opioids may also rise in the country, thereby resulting in several AE-related deaths. Therefore, to promote appropriate opioid use, training is being imparted to physicians, nurses, and pharmacists. By taking such initiatives, the government hopes there will be more responsible use of opioid drugs in the country, which will help in the growth of the market.

Daiichi Sankyo is a renowned pharmaceutical company, headquartered in Tokyo, Japan. With over 100 years of expertise, it provides a range of opioid analgesics to help patients in pain management. These include, Narusus® Tablets and Narurapid® Tablets, as well as injections like Naruvein® Injection, Oxycodone Injections 50 mg, and Oxycodone Injections 10 mg. The company lays a strong focus on R&D.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    ASIA-PACIFIC OPIOID DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. KEY INSIGHTS

2.2.1. TECHNOLOGICAL ADVANCEMENTS TO FIGHT AGAINST OPIOID DRUG CRISIS

2.2.2. DIFFERENT SOURCES OF PROCURING OPIOIDS

2.3. PORTER’S FIVE FORCE ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTE

2.3.3. BARGAINING POWER OF SUPPLIERS

2.3.4. BARGAINING POWER OF BUYERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. MARKET DRIVERS

2.6.1. GROWTH IN MEDICAL CASES & RISING PREVALENCE OF CANCER

2.6.2. INCREASE IN THE USE OF ABUSE-DETERRENT FORMULATIONS TO RESTRICT THE RISE OF OPIOID DEPENDENCE

2.6.3. DEMAND FOR PALLIATIVE THERAPY

2.7. MARKET RESTRAINTS

2.7.1. GOVERNMENT RULES & REGULATIONS

2.7.2. INCREASED NUMBER OF LAWSUITS AGAINST MANUFACTURERS OF OPIOID DRUGS

2.7.3. USAGE OF OPIOIDS FOR NON-MEDICAL PURPOSES

2.8. MARKET OPPORTUNITIES

2.8.1. RISING COMMERCIAL SUCCESS AND MARKET SHARE OF OPIOID DRUGS

2.8.2. GROWTH IN INVESTMENTS IN RESEARCH OF PHARMACEUTICAL USES OF OPIOIDS

2.9. MARKET CHALLENGES

2.9.1. OPIOIDS EPIDEMIC SPREAD

2.9.2. RISING DEATH RATE DUE TO OPIOIDS OVERDOSE

2.10. COVID-19 IMPACT ON THE OPIOID DRUGS MARKET

3.    ASIA-PACIFIC OPIOID DRUGS MARKET OUTLOOK - BY PRODUCT

3.1. BUPRENORPHINE

3.2. FENTANYL

3.3. HYDROCODONE

3.4. MORPHINE

3.5. OXYCODONE

3.6. TRAMADOL

3.7. OTHER PRODUCTS

4.    ASIA-PACIFIC OPIOID DRUGS MARKET OUTLOOK - BY APPLICATION

4.1. PAIN RELIEF

4.1.1. CANCER PAIN

4.1.2. POSTOPERATIVE PAIN MANAGEMENT

4.1.3. LOWER BACK PAIN

4.1.4. ORTHOPEDIC

4.1.5. NEUROPATHIC

4.1.6. FIBROMYALGIA

4.2. ANESTHESIA

4.3. COUGH SUPPRESSION

4.4. DIARRHEA SUPPRESSION

4.5. DE-ADDICTION

5.    ASIA-PACIFIC OPIOID DRUGS MARKET – REGIONAL OUTLOOK

       5.1. CHINA

       5.2. JAPAN

       5.3. INDIA

       5.4. SOUTH KOREA

       5.5. ASEAN COUNTRIES

       5.6. AUSTRALIA & NEW ZEALAND

       5.7. REST OF ASIA-PACIFIC

6.    COMPETITIVE LANDSCAPE

6.1. ACURA PHARMACEUTICALS

6.2. BIODELIVERY SCIENCES INTERNATIONAL INC

6.3. CIPHER PHARMACEUTICALS INC

6.4. ALLERGAN (ACQUIRED BY ABBVIE)

6.5. COLLEGIUM PHARMACEUTICAL INC

6.6. DAIICHI SANKYO

6.7. HIKMA PHARMACEUTICALS PLC

6.8. INDIVIOR INC

6.9. JANSSEN PHARMACEUTICALS INC

6.10. JOHNSON JOHNSON

6.11. LANNETT CO INC

6.12. LUPIN LTD

6.13. MYLAN NV

6.14. PFIZER INC

6.15. PURDUE PHARMA LP

6.16. SANOFI-AVENTIS SA

6.17. SUN PHARMACEUTICAL INDUSTRIES LTD

6.18. TEVA PHARMACEUTICAL INDUSTRIES LTD

7.    METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE & DELIVERABLES

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of table

TABLE 1: ASIA-PACIFIC OPIOID DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: ASIA-PACIFIC OPIOID DRUGS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC OPIOID DRUGS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC OPIOID DRUGS MARKET, BY PAIN RELIEF, 2019-2028 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC OPIOID DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)

List of Figures

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: MARKET ATTRACTIVENESS INDEX

FIGURE 3: ASIA-PACIFIC OPIOID DRUGS MARKET, BY BUPRENORPHINE, 2019-2028 (IN $ MILLION)

FIGURE 4: ASIA-PACIFIC OPIOID DRUGS MARKET, BY FENTANYL, 2019-2028 (IN $ MILLION)

FIGURE 5: ASIA-PACIFIC OPIOID DRUGS MARKET, BY HYDROCODONE, 2019-2028 (IN $ MILLION)

FIGURE 6: ASIA-PACIFIC OPIOID DRUGS MARKET, BY MORPHINE, 2019-2028 (IN $ MILLION)

FIGURE 7: ASIA-PACIFIC OPIOID DRUGS MARKET, BY OXYCODONE, 2019-2028 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC OPIOID DRUGS MARKET, BY TRAMADOL, 2019-2028 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC OPIOID DRUGS MARKET, BY OTHER PRODUCTS, 2019-2028 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC OPIOID DRUGS MARKET, BY PAIN RELIEF, 2019-2028 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC OPIOID DRUGS MARKET, BY CANCER PAIN, 2019-2028 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC OPIOID DRUGS MARKET, BY POSTOPERATIVE PAIN MANAGEMENT, 2019-2028 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC OPIOID DRUGS MARKET, BY LOWER BACK PAIN, 2019-2028 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC OPIOID DRUGS MARKET, BY ORTHOPEDIC, 2019-2028 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC OPIOID DRUGS MARKET, BY NEUROPATHIC, 2019-2028 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC OPIOID DRUGS MARKET, BY FIBROMYALGIA, 2019-2028 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC OPIOID DRUGS MARKET, BY ANESTHESIA, 2019-2028 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC OPIOID DRUGS MARKET, BY COUGH SUPPRESSION, 2019-2028 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC OPIOID DRUGS MARKET, BY DIARRHEA SUPPRESSION, 2019-2028 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC OPIOID DRUGS MARKET, BY DE-ADDICTION, 2019-2028 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC OPIOID DRUGS MARKET; REGIONAL OUTLOOK 2019 & 2028 (IN %)

FIGURE 22: CHINA OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 23: JAPAN OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 24: INDIA OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 25: SOUTH KOREA OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 26: ASEAN COUNTRIES OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 27: AUSTRALIA & NEW ZEALAND OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 28: REST OF ASIA-PACIFIC OPIOID DRUGS MARKET, 2019-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;